Telcon RF Pharmaceutical Inc
KOSDAQ:200230
Telcon RF Pharmaceutical Inc
Note Receivable
Telcon RF Pharmaceutical Inc
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Telcon RF Pharmaceutical Inc
KOSDAQ:200230
|
Note Receivable
₩47.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-35%
|
|
|
D
|
DreamTech Co Ltd
KRX:192650
|
Note Receivable
₩463.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
K
|
KH Electron Co Ltd
KOSDAQ:111870
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Pavonine Co Ltd
KOSDAQ:177830
|
Note Receivable
₩336.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
P
|
PJ Electronics Co Ltd
KOSDAQ:006140
|
Note Receivable
₩438.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Telcon RF Pharmaceutical Inc
Glance View
TELCON RF PHARMACEUTICAL.Inc. engages in the manufacture, development and sale of cable assemblies and medicinal products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2014-11-24. Inc., formerly TELCON.Inc, is a Korea-based company principally engaged in the manufacture and distribution of connectors and cable assemblies. The Company’s products mainly consist of radio frequency (RF) connectors, RF cables, couplers, dividers, arrestors, terminations, adapters, and other cable assemblies, which are used for wireless communication equipment.
See Also
What is Telcon RF Pharmaceutical Inc's Note Receivable?
Note Receivable
47.3m
KRW
Based on the financial report for Sep 30, 2025, Telcon RF Pharmaceutical Inc's Note Receivable amounts to 47.3m KRW.
What is Telcon RF Pharmaceutical Inc's Note Receivable growth rate?
Note Receivable CAGR 10Y
-35%
Over the last year, the Note Receivable growth was -33%. The average annual Note Receivable growth rates for Telcon RF Pharmaceutical Inc have been 20% over the past three years , and -35% over the past ten years .
